Deals, Development and Manufacturing

The companies plan to promote and manufacture Maverick, an emergency-use, cartridge-based auto-injector.

The transaction is expected to be finalized in early 2020.

GE Healthcare Life Sciences will supply Akeso Pharmaceuticals with the FlexFactory platform to accelerate production of antibody drugs in the Guangzhou region.

Schott will combine its adaptiQ platform with West’s Ready Pack system.

Despite preparative work by the bio/pharma industry, any Brexit scenario will result in regulatory implications and increased costs.

After years of discussions around pricing, UK governmental bodies and Vertex have finally reached an agreement on cystic fibrosis treatments.

Contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has revealed its investment of $1.5 million into a phased expansion of its facility based in North Carolina, United States.

Swiss-based company, BioVersys, has been granted funding worth up to $8.92 million by CARB-X to support the development of anti-virulence small molecule drugs that disarm bacteria, which could offer a paradigm shift in antimicrobial resistance (AMR) therapy.

Dassault Systèmes has announced the completion of its acquisition of Medidata Solutions, which will connect the 3DEXPERIENCE platform with a clinical trial platform and opens up virtual twin experiences for healthcare.

Intertek has announced that it has expanded its center of excellence for biopharmaceutical services in Manchester, United Kingdom, to support the development of biologics and gene therapies.

Start-up company, SeraNovo, has revealed that it has signed a license agreement with Carna Biosciences to expand the existing collaboration and jointly develop an oral formulation of Carna’s kinase inhibitor with increase bioavailability.

The partnership will center on the development and commercialization of DCR-HBVS, Dicerna’s investigational therapy in Phase I clinical development, using its proprietary RNAi platform technology.

The project will seek to deliver treatments for the underlying cause of cystic fibrosis through submitted proposals from potential collaborators.

The companies will develop innovative formulations for drugs to treat rare diseases using Catalent’s oral disintegrating tablet technologies.

Phillips-Medisize, a Molex company, revealed its agreement with a biotechnology company to manufacture a wearable electronic-enabled combination product.

Lincoln Pharmaceuticals has received a patent, which is valid for 20 years, from the Government of India for its liquid diclofenac metered-dose rectal spray.

A joint funding initiative, UKI2S Innovate Accelerator, has been providing funding for start-ups throughout the United Kingdom for 12 months.

Takeda Pharmaceutical Company has acquired an exclusive global license from COUR Pharmaceuticals for the development and commercialization of an investigational celiac disease therapy.

Sartorius has signed an agreement for the acquisition of parts of Danaher’s Life Science Portfolio in cash.

GE Healthcare has announced the inauguration of an open-access lab at the Mereside Campus of Alderley Park in the United Kingdom, which will be used to support acceleration of biotech, health, and life-sciences research.

The packaging solution works to protect drugs with a 3-Phase Activ-Polymer solution, a technology that is customized for the drug developer’s formulation, offers a broad spectrum of specific drug protection, and oxygen and odor scavenging.

The goal of the investment is for the cures to be made available across the globe, including in sub-Saharan Africa’s low-resource communities.

The partners have developed a scalable, cost-effective purification process for adeno-associated viruses.

The therapy received positive results in a randomized, double-blind, placebo-controlled clinical trial in 34 adults with proven celiac disease.

Under the agreement, gene and cell therapy companies can go directly to Aldevron for NTC’s technology without acquiring a license from NTC.

The company will produce the anti-HER3 antibody drug HMBD-001for use within a clinical partnership between Cancer Research UK and Hummingbird Bioscience to test the agent in a Phase I trial.

The transaction is set to be completed in the first quarter of 2020.

Through the agreement, Foamix will have access to $20 million of financing to fund the commercial launches of the topical treatments.

The transaction is anticipated to close by the end of 2019.

A complete understanding of primary packaging physicochemical properties is necessary in the formulation and development of biologics.